Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa.
Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data such as adherence to drug-refill visits as early warning indicator...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-03-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3052314?pdf=render |
id |
doaj-44c838c457db4cf9bcb628173d80171d |
---|---|
record_format |
Article |
spelling |
doaj-44c838c457db4cf9bcb628173d80171d2020-11-25T01:46:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-03-0163e1751810.1371/journal.pone.0017518Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa.Ziad El-KhatibZiad El-KhatibDavid KatzensteinGaetano MarroneFatima LaherLerato MohapiMax PetzoldLynn MorrisAnna Mia EkströmAffordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data such as adherence to drug-refill visits as early warning indicators. We examined the association between adherence to drug-refill visits and long-term virologic and immunologic failure among non-nucleoside reverse transcriptase inhibitor (NNRTI) recipients in South Africa.In 2008, 456 patients on NNRTI-based ART for a median of 44 months (range 12-99 months; 1,510 person-years) were enrolled in a retrospective cohort study in Soweto. Charts were reviewed for clinical characteristics before and during ART. Multivariable logistic regression and Kaplan-Meier survival analysis assessed associations with virologic (two repeated VL>50 copies/ml) and immunologic failure (as defined by WHO).After a median of 15 months on ART, 19% (n = 88) and 19% (n = 87) had failed virologically and immunologically respectively. A cumulative adherence of <95% to drug-refill visits was significantly associated with both virologic and immunologic failure (p<0.01). In the final multivariable model, risk factors for virologic failure were incomplete adherence (OR 2.8, 95%CI 1.2-6.7), and previous exposure to single-dose nevirapine or any other antiretrovirals (adj. OR 2.1, 95%CI 1.2-3.9), adjusted for age and sex. In Kaplan-Meier analysis, the virologic failure rate by month 48 was 19% vs. 37% among adherent and non-adherent patients respectively (logrank p value = 0.02).One in five failed virologically after a median of 15 months on ART. Adherence to drug-refill visits works as an early warning indicator for both virologic and immunologic failure.http://europepmc.org/articles/PMC3052314?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ziad El-Khatib Ziad El-Khatib David Katzenstein Gaetano Marrone Fatima Laher Lerato Mohapi Max Petzold Lynn Morris Anna Mia Ekström |
spellingShingle |
Ziad El-Khatib Ziad El-Khatib David Katzenstein Gaetano Marrone Fatima Laher Lerato Mohapi Max Petzold Lynn Morris Anna Mia Ekström Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS ONE |
author_facet |
Ziad El-Khatib Ziad El-Khatib David Katzenstein Gaetano Marrone Fatima Laher Lerato Mohapi Max Petzold Lynn Morris Anna Mia Ekström |
author_sort |
Ziad El-Khatib |
title |
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. |
title_short |
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. |
title_full |
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. |
title_fullStr |
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. |
title_full_unstemmed |
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. |
title_sort |
adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among hiv patients on first-line art in south africa. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-03-01 |
description |
Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data such as adherence to drug-refill visits as early warning indicators. We examined the association between adherence to drug-refill visits and long-term virologic and immunologic failure among non-nucleoside reverse transcriptase inhibitor (NNRTI) recipients in South Africa.In 2008, 456 patients on NNRTI-based ART for a median of 44 months (range 12-99 months; 1,510 person-years) were enrolled in a retrospective cohort study in Soweto. Charts were reviewed for clinical characteristics before and during ART. Multivariable logistic regression and Kaplan-Meier survival analysis assessed associations with virologic (two repeated VL>50 copies/ml) and immunologic failure (as defined by WHO).After a median of 15 months on ART, 19% (n = 88) and 19% (n = 87) had failed virologically and immunologically respectively. A cumulative adherence of <95% to drug-refill visits was significantly associated with both virologic and immunologic failure (p<0.01). In the final multivariable model, risk factors for virologic failure were incomplete adherence (OR 2.8, 95%CI 1.2-6.7), and previous exposure to single-dose nevirapine or any other antiretrovirals (adj. OR 2.1, 95%CI 1.2-3.9), adjusted for age and sex. In Kaplan-Meier analysis, the virologic failure rate by month 48 was 19% vs. 37% among adherent and non-adherent patients respectively (logrank p value = 0.02).One in five failed virologically after a median of 15 months on ART. Adherence to drug-refill visits works as an early warning indicator for both virologic and immunologic failure. |
url |
http://europepmc.org/articles/PMC3052314?pdf=render |
work_keys_str_mv |
AT ziadelkhatib adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT ziadelkhatib adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT davidkatzenstein adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT gaetanomarrone adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT fatimalaher adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT leratomohapi adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT maxpetzold adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT lynnmorris adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica AT annamiaekstrom adherencetodrugrefillisausefulearlywarningindicatorofvirologicandimmunologicfailureamonghivpatientsonfirstlineartinsouthafrica |
_version_ |
1725018083740876800 |